DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
5 Top Value Stocks to Buy in a Volatile April
by Nalak Das
Volatility is likely to persist in April as the panoptic impact of the coronavirus outbreak is yet to be realized in the United States and globally.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
DaVita HealthCare (DVA) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $76.06, moving -0.46% from the previous trading session.
Top Ranked Growth Stocks to Buy for March 31st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 31st
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
Zacks.com featured highlights include: ITOCHU, Am??rica M??vil, Donegal, DaVita and The Cardinal Health
by Zacks Equity Research
Zacks.com featured highlights include: ITOCHU, Am??rica M??vil, Donegal, DaVita and The Cardinal Health
Use Relative Price Strength to Survive the Coronavirus Hysteria
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns in the time of coronavirus? Tap these stocks with explosive relative price strength.
DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $75.27 in the latest trading session, marking a +0.19% move from the prior day.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
DaVita HealthCare (DVA) Down 12.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Ranked Growth Stocks to Buy for March 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 10th
CVS Health's Latest Alliances to Fortify Kidney-Care Business
by Zacks Equity Research
With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.
Time to Focus on DaVita (DVA) for Strong Earnings Growth Potential
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).
Why DaVita (DVA) Stock Might be a Great Pick
by Zacks Equity Research
DaVita (DVA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Top Ranked Growth Stocks to Buy for February 27th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 27th
Why DaVita (DVA) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).
Why DaVita (DVA) Could Be Positioned for a Surge
by Zacks Equity Research
DaVita (DVA) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
Top Ranked Growth Stocks to Buy for February 19th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 19th
5 Stocks in Focus on Remarkable Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma